Here's Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10

Stocks and Investing Stocks and Investing

Tue, January 7, 2025

[ 12:21 PM ] - Kiplinger

Meta Adds Dana White to Its Board, Ends Fact-Checking: What to Know

[ 11:41 AM ] - Kiplinger

Why McDonald's Is Still a Buy After Rolling Back DEI Initiatives

[ 11:35 AM ] - WOPRAI

40 Earnings Releases for Jan 07th, 2025

[ 11:21 AM ] - MSN

Is It Worth Investing in Alibaba (BABA) Based on Wall Street's Bullish Views?

[ 11:21 AM ] - Investopedia

Is Forex Buy-and-Hold Trading the Investing Strategy You've Been Missing?

[ 11:01 AM ] - MSN

Unlocking value: These 6 mutual funds offered ove .. nual returns in last 10 years; should you invest?

[ 10:41 AM ] - MarketWatch

Stock Market Today: Dow pares earlier gains following jobs data

[ 10:41 AM ] - TechRepublic

Microsoft to Invest $80 Billion in AI Data Centers in Fiscal 2025

[ 10:41 AM ] - MSN

3 big gold investing mistakes to avoid in 2025

[ 10:01 AM ] - MSN

3 Undervalued Companies Warren Buffett Invested In During 2024: Should You Buy These Stocks?

[ 09:41 AM ] - MSN

Build a Bulletproof Portfolio with These Three Diversified Dividend Stocks

[ 09:21 AM ] - MSN

UK sees surge in crypto ownership with 7 million Brits investing in digital assets

[ 08:01 AM ] - Sky

Money blog: High street chain with 364 stores 'accelerating closures' due to budget

[ 07:01 AM ] - MSN

Top 3 Contra Mutual Funds With Best SIP Returns i .. nvestment in No. 1 fund is now worth Rs 12,00,878

[ 06:41 AM ] - MSN

Here's Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10

[ 06:41 AM ] - MSN

Should The Coca-Cola Company (NYSE:KO) Be In Your Early Retirement Portfolio?

[ 06:21 AM ] - MarketWatch

10 financial advisers on their No. 1 piece of money advice for 2025

[ 05:41 AM ] - MSN

Watch out, this UK stock's already jumped out of the blocks for 2025!

[ 05:21 AM ] - MSN

Warren Buffett's Warning to Wall Street Reached D .. in 2024. Here's What to Do as 2025 Gets Started.

[ 01:21 AM ] - Forbes

Angel One Review 2025: Features, Pros & Cons

[ 01:01 AM ] - MSN

Investors Look Back at 2024

[ 12:01 AM ] - MarketWatch

Stock Market Today: Dow ends lower while Nasdaq logs best start to a year since 2009

Mon, January 6, 2025

[ 11:41 PM ] - MSN

Best small cap mutual funds to invest in January 2025

[ 10:01 PM ] - MSN

Invest $30,000 in 2 TSX Stocks and Create $611.52 in Dividend Income

[ 09:41 PM ] - MSN

Here's How Much 35-Year-Old Canadians Need Now to Retire at 65

[ 09:01 PM ] - MSN

Here's Why Paycor HCM Inc. (NASDAQ:PYCR) Is Skyrocketing

[ 08:41 PM ] - esquiremag

Financial Adviser: 5 Investing Resolutions for 2025 and How to Achieve Them

[ 07:41 PM ] - MSN

The CRA Is Watching: TFSA Investors Should Avoid These Red Flags

[ 07:41 PM ] - MSN

What are Intrusion-related Gold Systems?

[ 07:01 PM ] - MSN

Here's Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10

^{Published on 2025-01-06 19:01:10 - MSN}

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Biomea Fusion, Inc. (NASDAQ:BMEA) stands against the other diabetes stocks.

The article from MSN Money discusses why Biomea Fusion Inc. (NASDAQ: BMEA) is considered one of the best diabetes stocks to buy under $10. Biomea Fusion is a clinical-stage biopharmaceutical company focusing on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases like diabetes. The company's lead candidate, BMF-219, is a novel covalent menin inhibitor currently in clinical trials for both diabetes and certain types of cancer. The article highlights that Biomea's stock has shown significant volatility but has potential due to its innovative approach to treating diabetes through targeting the menin-MLL interaction, which could offer a new therapeutic pathway for managing the disease. Furthermore, the company's recent positive data from early-stage trials and its relatively low market cap make it an attractive option for investors looking for high-risk, high-reward opportunities in the biotech sector.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/savingandinvesting/here-s-why-biomea-fusion-inc-nasdaq-bmea-is-among-the-best-diabetes-stocks-to-buy-under-10/ar-AA1x2ZaP ]

Contributing Sources